A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells

S. Roman-Unfer, J. D. Bitran*, L. Garrison, C. Proeschel, S. Hanauer, L. Schroeder, L. Johnson, L. Klein, J. Martinec

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Fourteen patients with stage II-IV breast cancer were enrolled in a phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood progenitor cells (PBPC). All 14 women tolerated PIXY321 well, with the predominant toxicities being erythema at the injection site, fever, and arthralgias. A median of two aphereses yielded a mean of 1.3 x 108 mononuclear cells/kg, 8.9 x 104 colony-forming units-granulocyte/macrophage (CFU-GM)/kg, and 4.5 x 106 CD34+ cells/kg. All 14 patients underwent high-dose chemotherapy with PBPC support, the median day to ANC >500 cells/μF IL was 10.6, and the median day to platelets 220,000 cells/μL was 13. The day of 90th percentile platelet recovery was 15. When compared to PBPCs mobilized by cyclophosphamide followed by GM-CSF, the use of PIXY321 may confer an advantage of enhanced platelet recovery.

Original languageEnglish (US)
Pages (from-to)823-828
Number of pages6
JournalExperimental Hematology
Volume24
Issue number7
StatePublished - Jul 22 1996

Keywords

  • Breast cancer
  • Mobilized peripheral blood progenitor cells
  • PIXY321

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells'. Together they form a unique fingerprint.

Cite this